Placental growth factor (PlGF)-specific uptake in tumor microenvironment of 89Zr-labeled PlGF antibody RO5323441

Journal of Nuclear Medicine

Volumn 54, Issue 6, 2013, Pages 929-935

  Oude Munnink, Thijs H ^a   Tamas, Karin R ^a   Lub de Hooge, Marjolijn N ^a   Vedelaar, Silke R ^a   Timmer Bosscha, Hetty ^a   Walenkamp, Annemiek M E ^a   Weidner, K Michael ^b   Herting, Frank ^b   Tessier, Jean ^c   De Vries, Elisabeth G E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

89Zr; Angiogenesis; Placental growth factor; Positron emission tomography; RO5323441

Indexed keywords

IMMUNOGLOBULIN G IN 111; MONOCLONAL ANTIBODY; PLACENTAL GROWTH FACTOR; PLACENTAL GROWTH FACTOR ANTIBODY; RO 5323441; RO 5323441 ZR 89; TRACER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; CARCINOMA CELL; CELL STRAIN; CELL STRAIN HUH7; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG STABILITY; DRUG TUMOR LEVEL; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VITRO STUDY; ISOTOPE LABELING; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; ORGAN DISTRIBUTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TIME; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; VALIDATION STUDY;

89ZR; ANGIOGENESIS; PLACENTAL GROWTH FACTOR; POSITRON EMISSION TOMOGRAPHY; RO5323441;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL TRANSPORT; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOTOPE LABELING; KIDNEY NEOPLASMS; MACROPHAGES; MALE; MICE; PREGNANCY PROTEINS; RADIOISOTOPES; TUMOR MICROENVIRONMENT; ZIRCONIUM;

EID: 84878648598     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.112086     Document Type: Article

References (29)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
2. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358:2039-2049. (Pubitemid 351656458)
3. Fan F, Samuel S, Gaur P, et al. Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration. Br J Cancer. 2011;104:1270-1277.
4. Fischer C, Mazzone M, Jonckx B, Carmeliet P. FLT1 and its ligands VEGF-B and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer. 2008;8:942-956.
5. Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15:220-231.
6. Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 2001;7:575-583. (Pubitemid 32448325)
7. Fischer C, Jonckx B, Mazzone M, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell. 2007;131:463-475. (Pubitemid 350007692)
8. van de Veire S, Stalmans I, Heindryckx F, et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell. 2010;141:178-190.
9. Nielsen DL, Sengeløv L. Inhibition of placenta growth factor with TB-403: a novel antiangiogenic cancer therapy. Expert Opin Biol Ther. 2012;12:795-804.
10. Martinsson-Niskanen T, Riisbro R, Larsson L, et al. Monoclonal antibody TB-403: a first-in-human, phase I, double-blind, dose escalation study directed against placental growth factor in healthy male subjects. Clin Ther. 2011;33:1142-1149.
11. Lassen U, Nielsen DL, Sørensen M, et al. A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumours. Br J Cancer. 2012;106:678-684.
12. Nagengast WB, de Vries EG, Hospers GA, et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med. 2007;48:1313-1319. (Pubitemid 47242797)
13. 89Zr- bevacizumab PET imaging in renal cell carcinoma patients: feasibility of tumor VEGF quantification. Eur J Cancer. 2010;7:72-73.
14. 111Inbevacizumab in stage III/IV melanoma patients. Eur J Cancer. 2011;47:1595-1602.
15. 89Zr-labeled monoclonal antibodies. J Nucl Med. 2003;44:1271-1281.
16. 89Zr-labeled transforming growth factor-β antibody fresolimumab in tumor models. J Nucl Med. 2011;52:2001-2008.
17. Stollman TH, Scheer MG, Leenders WP, et al. Specific imaging of VEGF-A expression with radiolabeled anti-VEGF monoclonal antibody. Int J Cancer. 2008;122:2310-2314. (Pubitemid 351542336)
18. Migdal M, Huppertz B, Tessler S, et al. Neuropilin-1 is a placenta growth factor-2 receptor. J Biol Chem. 1998;273:22272-22278. (Pubitemid 28399784)
19. Hogarth PM, Pietersz GA. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat Rev Drug Discov. 2012;11:311-331.
20. Meyer T, Robles-Carrillo L, Robson T, et al. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost. 2009;7:171-181.
21. Ribatti D. The controversial role of placental growth factor in tumor growth. Cancer Lett. 2011;307:1-5.
22. Deprimo SE, Bello CL, Smeraglia J, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med. 2007;5:32.
23. Willett CG, Duda DG, di Tomaso E, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol. 2009;27:3020-3026.
24. Kopetz S, Hoff PM, Morris JS, et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2010;28:453-459.
25. Bagley RG, Ren Y, Weber W, et al. Placental growth factor upregulation is a host response to antiangiogenic therapy. Clin Cancer Res. 2011;17:976-988.
26. Pastuskovas CV, Mundo EE, Williams SP, et al. Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol Cancer Ther. 2012;11:752-762.
27. Bais C, Wu X, Yao J, et al. PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell. 2010;141:166-177.
28. Yao J, Wu X, Zhuang G, et al. Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy. Proc Natl Acad Sci USA. 2011;108:11590-11595.
29. Rolny C, Mazzone M, Tugues S, et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell. 2011;19:31-44.